Angioplasty in Aspirin-Free Stable Patients with Prasugrel: Innovation Continues

Potent P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, have been tested mainly in a setting of acute coronary syndromes. There is little evidence on stable patients, particularly for prasugrel. Designing a study with that purpose seemed challenging enough, but adding aspirin discontinuation in patients without a particularly high bleeding risk took this research to another level.

Angioplastia en pacientes estables sin aspirina y con prasugrel

The working hypothesis was that prasugrel monotherapy after successful angioplasty with an everolimus-eluting stent could be safe and effective in a population with stable coronary disease.

The most recent papers have pushed a short or ultra-short aspirin use time in patients with an overall high bleeding risk.

This paper, published in JACC Cardiovasc Interv., took it a step further by skipping aspirin altogether in a low-risk population (SYNTAX score <23) who underwent elective angioplasty.

All patients were receiving dual antiplatelet therapy at the time of the procedure (even on the actual day it was conducted), and aspirin was discontinued immediately after successful angioplasty. Prasugrel was administered in the cath lab immediately after the procedure and was continued as monotherapy for only 3 months.


Read also: Dual Layered for Dual Protection in Carotid PCI.


The primary endpoint was a composite of cardiac death, vessel-related infarction, definite thrombosis, and major bleeding (Bleeding Academic Research Consortium types 3 to 5).

Of 201 enrolled patients, there was an event in one patient (0.5%). There were no cases of stent thrombosis.

Conclusion

Prasugrel monotherapy after successful elective angioplasty with everolimus-eluting stent in a population with simple anatomy proved safe and effective. These findings promote designing higher-scale studies to define the right balance between ischemic and hemorrhagic risk.

Original Title: Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. The ASET Pilot Study.

Reference: Norihiro Kogame et al. JACC Cardiovasc Interv. 2020 Oct 12;13(19):2251 2262. doi: 10.1016/j.jcin.2020.06.023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....